ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy - including in Difficult-to-Treat Manifestations - Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function

Newly reported data in key disease manifestations including dactylitis and nail lesions to be presented at the American College of Rheumatology (ACR) Convergence 2022 Combined with previously reported differentiated data [...]